The STA-Staclot DRVV Screen utilizes a low phospholipid reagent, which enhances its sensitivity to the presence of LA, resulting in a prolonged clotting time while the STA Staclot DRVV Confirm utilizes a high phospholipid reagent, which neutralizes LA present in the plasma resulting in a shortened clotting time. The tests are unaffected by contact factor deficiencies, factor VIII and IX deficiencies or other
specific inhibitors. The assay is not affected by samples containing therapeutic heparin levels.
“The addition of STA-Staclot DRVV Screen and STA-Staclot DRVV Confirm assays to our lupus testing product line means that our customers now have a full range of lupus testing assays to meet their needs,” explains Bob Bachkosky, Director of Marketing at Diagnostica Stago.
STA-Staclot DRVV Screen and STA-Staclot DRVV Confirm, when used in conjunction with Staclot LA, fulfill the recommendations for diagnosis of lupus anticoagulants established by the Scientific Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the International Society on
Thrombosis and Haemostasis (ISTH).*
*Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737–40